Human GHR, Fc Tag (GHR-H5257) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Tyr 264 (Accession # P10912).
Predicted N-terminus: Ala 27
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 54.3 kDa. As a result of glycosylation, the protein migrates as 66-85 kDa under reducing (R) condition, and 135-160 kDa under non-reducing (NR) condition (SDS-PAGE).
Less than 1.0 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Human GHR, Fc Tag on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Human GH, Tag Free at 2 μg/mL (100 μL/well) can bind Human GHR, Fc Tag (Cat. No. GHR-H5257) with a linear range of 0.2-3 ng/mL (QC tested).
Growth hormone receptor (GHR) is also known as somatotropin receptor, growth hormone-binding protein (GHBR), which belongs to the type I cytokine receptor family or Type 1 subfamily. GHR contains one fibronectin type-III domain. GHR / GHBR is expressed in various tissues with high expression in liver and skeletal muscle. The soluble form (GHBP) is produced by phorbol ester-promoted proteolytic cleavage at the cell surface (shedding) by ADAM17/TACE. GHR is receptor for pituitary gland growth hormone involved in regulating postnatal body growth. On ligand binding, couples to the JAK2/STAT5 pathway. The soluble form (GHBP) acts as a reservoir of growth hormone in plasma and may be a modulator/inhibitor of GH signaling.